共 26 条
[1]
Keating GM(2012)Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy CNS Drugs 26 787-790
[2]
Duggan ST(2011)Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study Support Care Cancer 19 1609-1617
[3]
Curran MP(2006)Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy J Support Oncol 4 35-41
[4]
Boccia RV(2003)Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron Cancer 98 2473-2482
[5]
Gordan LN(2012)Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron Clin Cancer Res 18 2913-2921
[6]
Clark G(2009)Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting J Oncol Pharm Pract 15 223-231
[7]
Howell JD(2010)Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review Cancer Manag Res 2 1-12
[8]
Grunberg SM(2003)Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control Oncologist 8 187-198
[9]
Decker GM(undefined)undefined undefined undefined undefined-undefined
[10]
DeMeyer ES(undefined)undefined undefined undefined undefined-undefined